{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-019219","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.222212+00:00","generated_at":"2026-05-20T01:57:48.257980+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Allarity enrolls first patient in Phase 2 stenoparib trial for advanced ovarian cancer","bullets":["First patient dosed in new Phase 2 protocol for platinum-resistant or platinum-ineligible advanced ovarian cancer.","Trial includes DRP companion diagnostic to enrich for stenoparib responders.","Two patients remain on prior Phase 2 study on twice-daily dosing, deriving benefit beyond 20 months.","Additional dosing level added aligning with FDA Project Optimus to inform pivotal trial design.","Company expects significant clinical data by late summer 2026; pursuing accelerated regulatory pathways."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-019219","json":"https://secwatch.observer/filing/0001437749-25-019219.json","markdown":"https://secwatch.observer/filing/0001437749-25-019219.md","text":"https://secwatch.observer/filing/0001437749-25-019219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925019219/0001437749-25-019219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925019219/allr20250602_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T01:57:48.257980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}